This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.bbc.co.uk/news/uk-england-cambridgeshire-63761765
The article has changed 7 times. There is an RSS feed of changes available.
| Version 2 | Version 3 |
|---|---|
| Covid: Blood thinner ineffective for patients, trial finds | Covid: Blood thinner ineffective for patients, trial finds |
| (3 months later) | |
| The trial involved patients in hospitals across the UK | The trial involved patients in hospitals across the UK |
| A possible treatment for severe Covid "puts patients at risk for no clear benefit", a trial found. | A possible treatment for severe Covid "puts patients at risk for no clear benefit", a trial found. |
| More than 1,000 people took part in the UK-wide trial of the blood thinner Apixaban while in hospital with Covid. | More than 1,000 people took part in the UK-wide trial of the blood thinner Apixaban while in hospital with Covid. |
| The Addenbrooke's Hospital and University of Cambridge study aims to find a treatment to prevent death from Covid, and readmission to hospital. | The Addenbrooke's Hospital and University of Cambridge study aims to find a treatment to prevent death from Covid, and readmission to hospital. |
| It found the drug had no impact, but some patients did experience side effects including major bleeding. | It found the drug had no impact, but some patients did experience side effects including major bleeding. |
| 'Change medical practice' | 'Change medical practice' |
| Dr Mark Toshner, joint chief investigator for the trial, said it had been assumed that Apixaban could help patients recover from severe Covid. | Dr Mark Toshner, joint chief investigator for the trial, said it had been assumed that Apixaban could help patients recover from severe Covid. |
| "This trial is the first robust evidence that longer anticoagulation after acute Covid-19 puts patients at risk for no clear benefit," he said. | "This trial is the first robust evidence that longer anticoagulation after acute Covid-19 puts patients at risk for no clear benefit," he said. |
| "Our hope is that these results will stop this drug being needlessly prescribed to patients with Covid-19 and we can change medical practice." | "Our hope is that these results will stop this drug being needlessly prescribed to patients with Covid-19 and we can change medical practice." |
| Speaking to the BBC last year, Dr Charlotte Summers said the drugs were "relatively cheap" and "widely available" | Speaking to the BBC last year, Dr Charlotte Summers said the drugs were "relatively cheap" and "widely available" |
| The study found a small number of the 402 patients receiving Apixaban had to discontinue treatment due to major bleeding, a known side-effect. | The study found a small number of the 402 patients receiving Apixaban had to discontinue treatment due to major bleeding, a known side-effect. |
| Prof Charlotte Summers, an intensive care specialist at Addenbrooke's and the University of Cambridge, was the chief investigator for the trial. | Prof Charlotte Summers, an intensive care specialist at Addenbrooke's and the University of Cambridge, was the chief investigator for the trial. |
| "This finding is important because it will prevent unnecessary harm occurring to people for no benefit," she said. | "This finding is important because it will prevent unnecessary harm occurring to people for no benefit," she said. |
| "It also means we must continue our search for therapies that improve longer-term recovery for this devastating disease. | "It also means we must continue our search for therapies that improve longer-term recovery for this devastating disease. |
| "There is an urgent need for us to find treatments that prevent this significant burden of illness and improve the lives of so many still being affected by Covid." | "There is an urgent need for us to find treatments that prevent this significant burden of illness and improve the lives of so many still being affected by Covid." |
| The trial, funded by National Institute for Health and Care Research (NIHR) and the Cambridge NIHR Biomedical Research Centre, will continue to test another medicines - a statin called atorvastatin that acts on other mechanisms of disease that are thought to be important in Covid. | The trial, funded by National Institute for Health and Care Research (NIHR) and the Cambridge NIHR Biomedical Research Centre, will continue to test another medicines - a statin called atorvastatin that acts on other mechanisms of disease that are thought to be important in Covid. |
| Find BBC News: East of England on Facebook, Instagram and Twitter. If you have a story suggestion email eastofenglandnews@bbc.co.uk | Find BBC News: East of England on Facebook, Instagram and Twitter. If you have a story suggestion email eastofenglandnews@bbc.co.uk |
| Related Topics | Related Topics |
| Clinical trials | Clinical trials |
| Long Covid | Long Covid |
| Addenbrooke’s Hospital | Addenbrooke’s Hospital |
| Cambridge | Cambridge |
| Health | |
| University of Cambridge | University of Cambridge |
| Coronavirus pandemic | Coronavirus pandemic |